Padarn Therapeutics Inc. has described CDK2/cyclin A2 and CDK1/cyclin A2 inhibitors reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has described pyrazole-substituted cyclopentanol ester derivatives acting as CDK2/cyclin E1 and CDK2/cyclin A2 inhibitors reported to be useful for the ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced ...
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet ...
Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...
Small-cell lung cancer (SCLC) is an aggressive cancer with limited treatment options. Nearly all cases show deregulation in cell cycle progression, a therapeutic vulnerability that can be exploited.
WILMINGTON, DE — NiKang Therapeutics Inc. announced it has completed dosing in the first patient cohort of its Phase 1 dose-escalation study evaluating NKT5097, an oral small molecule designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback